Men who have received radiation treatment for prostate cancer within the last 5 years are needed. One blood draw is required. The Investigator will then check the blood samples for specific markers. These markers will then be compared to possible side effects that have been experienced from radiation treatment. Individuals react to medical treatment differently. The goal of the study is to be able to determine the dose of radiation treatment that is best suited for each man by checking these markers before he begins his treatment.
Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, and luteinizing hormone-releasing hormone aganist, may lessen the amount of androgens made by the body. It is not yet known which regimen of radiation therapy with or without androgen deprivation therapy is more effective for prostate cancer.
This randomized phase III trial is studying prostate radiation therapy to see how well it works compared with short-term androgen deprivation therapy given together with pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising PSA after surgery for prostate cancer. Patients will be randomly assigned to one of three study groups: radiation therapy to the prostate bed only; hormone therapy plus radiation to the prostate bed; and hormone therapy plus radiation to the prostate bed and to the pelvic lymph nodes.